Alnylam (ALNY) considered as a candidate for S&P 500 entry
FROM THE WIRE · FINANCE.YAHOO.COM
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is a biotechnology company built on RNA interference, a technique that switches off the genes behind certain diseases. At about $31 billion, the stock features on our list of 9 New Contenders for the S&P 500 Index. It stands out as a…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishPossible S&P 500 inclusion can generate buying demand for the stock.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Alnylam, at about $31 billion, is on the list of 9 new contenders for the S&P 500.
- 02The company is a biotech that has turned sustainably profitable under standard accounting rules.
- 03Its trailing price-to-earnings ratio is near 44 times, while the forward multiple is 20.
NEWS IMPACT AND MARKET REACTIONChange from the reference price
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets